Clinical Trials

WASHINGTON — In a Healio video exclusive, Shirley Paski, MD, discusses highlights from her presentation at Digestive Disease Week, which focused on the importance of screening patients on special diets for nutritional risks and malnutrition.

EyeCRO announced that its Microemulsion Drug Ocular Penetration System, or MiDROPS, demonstrated safety and efficacy in its first clinical application as a topical eye drop vehicle for dry eye disease.

DENVER — Treatment with a novel therapeutic led to clinically significant improvement in cognition for young persons with Angelman syndrome, Kemi Olugemo, MD, FAAN, said in this Healio video at the American Academy of Neurology annual meeting.

WASHINGTON — In a Healio video exclusive, Saqr Alsakarneh, MD, MSc, describes “significant disparities” in race, ethnicity and sex among participants enrolled clinical trials for liver transplantation in the U.S.

DENVER — A combination therapy of ciprofloxacin and celecoxib demonstrated a favorable safety profile for those with amyotrophic lateral sclerosis, Merit Cudkowicz, MD, MSc, said in this Healio video.

Aldeyra Therapeutics has enrolled the first patient in a phase 3 clinical trial designed to allow possible resubmission of the new drug application of topical 0.25% reproxalap for dry eye disease, according to a company press release.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Pravin U. Dugel, MD, of Ocular Therapeutix, overviews clinical results for Axpaxli, an axitinib implant for wet age-related macular degeneration.

The FDA has granted breakthrough therapy designation to a proprietary oligonucleotide conjugate for the treatment of myotonic dystrophy type 1, according to the manufacturer.

Geographic disparities in the availability of cancer clinical trials throughout the United States have worsened over time, according to study data published in JAMA Network Open.

DENVER — Losmapimod treatment for those with facioscapulohumeral muscular dystrophy led to no serious adverse events across three clinical trials, according to a poster at the American Academy of Neurology annual meeting.